Ozempic and blood pressure: what one person's story can and can't tell you

What did @plussizebeauty941 actually say?

The caption, not the audio, carries the actual health claim here. She wrote that after starting Ozempic "a few months ago," she went from taking 6 blood pressure medications down to 1, and says she "feels amazing." She's clear that her journey is personal and "everyone's journey won't be the same." The audio in this video is unrelated to the health content entirely, so every claim we're evaluating comes from the written caption.

That framing matters. She isn't prescribing anything, selling anything, or telling anyone to do what she did. She's documenting a personal result. That's a meaningfully different kind of claim than a medical professional making therapeutic promises, and it deserves to be evaluated as such.

Does the science back this up?

Yes, actually, and more robustly than most people expect. The connection between semaglutide-driven weight loss and blood pressure reduction is well-documented in clinical literature.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks, with meaningful reductions in systolic blood pressure. The SELECT trial (Lincoff et al., 2023, NEJM) followed over 17,000 adults with cardiovascular risk and found semaglutide significantly reduced major adverse cardiovascular events, including outcomes tied to hypertension burden.

Separately, a 2022 analysis in Hypertension (Jordan et al.) found that even modest weight loss of 5-10% can reduce systolic blood pressure by 3-8 mmHg, which compounds quickly across multiple medication thresholds. Going from 6 antihypertensives to 1 is a dramatic reduction, but for someone who was significantly obese and lost substantial weight, it is clinically plausible.

What did they get wrong (or right)?

She got the core claim right. Blood pressure improvement is one of the better-documented downstream effects of GLP-1-driven weight loss, and her experience tracks with what the data shows.

The one thing worth flagging is not something she said wrong, it's something the framing could accidentally imply. Reducing from 6 medications to 1 is not a typical outcome, and not something anyone should expect or plan for when starting Ozempic. Her own caveat, "everyone's journey won't be the same," is doing real work here. That line should not get scrolled past.

It's also worth noting that medication discontinuation should always be supervised by a prescribing physician. She doesn't say she stopped them herself, and there's no reason to assume she did, but anyone watching this video and thinking about reducing their own blood pressure medications needs to do that with a doctor, not based on a TikTok caption.

What should you actually know?

Ozempic (semaglutide 1mg) is FDA-approved for type 2 diabetes management. Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition. Blood pressure reduction is a recognized secondary benefit, not the primary indication.

The American Heart Association's 2023 guidance acknowledges GLP-1 receptor agonists as having cardiometabolic benefits beyond glucose control, which is why you're increasingly seeing them discussed in hypertension and cardiovascular risk contexts. But "recognized benefit" is not the same as "guaranteed outcome."

Side effects are real and range from nausea and vomiting (most common) to rarer risks including pancreatitis and, based on rodent studies, a theoretical thyroid C-cell tumor risk. That last one has not been confirmed in humans but carries an FDA black box warning. Anyone considering semaglutide should have that conversation with a licensed provider, not crowdsource it from social media.